Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensovibep in hospitalized COVID-19 patients (ACTIV-3/TICO H5)
NCT05780463Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Carrier/Scaffold Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of ensovibep in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2021; status: completed.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05780463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780463.